A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
Clinical trial NCT03809663 · TERMINATED
Trial details
- NCT number
- NCT03809663
- Sponsor
- Amgen
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-15
- Primary completion
- 2020-05-12
- Enrollment
- 251
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.